CO2022002731A2 - Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma - Google Patents

Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma

Info

Publication number
CO2022002731A2
CO2022002731A2 CONC2022/0002731A CO2022002731A CO2022002731A2 CO 2022002731 A2 CO2022002731 A2 CO 2022002731A2 CO 2022002731 A CO2022002731 A CO 2022002731A CO 2022002731 A2 CO2022002731 A2 CO 2022002731A2
Authority
CO
Colombia
Prior art keywords
solid state
state forms
neopentylamino
pentanamide
tetrahydronaphthalen
Prior art date
Application number
CONC2022/0002731A
Other languages
English (en)
Inventor
Ekaterina Albert
Stephen Anderson
Elaine Greer
Mark Maloney
Emily Rigsbee
Shu Yu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO2022002731A2 publication Critical patent/CO2022002731A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se relaciona con: a) formas en estado sólido de las sales bromhidrato del Compuesto 1; b) composiciones farmacéuticas que comprenden una o más formas en estado sólido de las sales bromhidrato del Compuesto 1, y, opcionalmente, un portador farmacéuticamente aceptable; c) métodos de tratamiento de tumores o de cánceres por medio de la administración de una o más formas en estado sólido de las sales bromhidrato del Compuesto 1 a un sujeto en necesidad de ello; y d) métodos para la preparación de las formas en estado sólido del Compuesto 1.
CONC2022/0002731A 2019-08-09 2022-03-09 Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma CO2022002731A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/045948 WO2021029854A1 (en) 2019-08-09 2019-08-09 Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Publications (1)

Publication Number Publication Date
CO2022002731A2 true CO2022002731A2 (es) 2022-05-20

Family

ID=67734850

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0002731A CO2022002731A2 (es) 2019-08-09 2022-03-09 Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma

Country Status (13)

Country Link
EP (1) EP4010322A1 (es)
JP (1) JP2022553479A (es)
KR (1) KR20220062510A (es)
CN (1) CN114555562A (es)
AR (1) AR119614A1 (es)
AU (1) AU2019461090A1 (es)
BR (1) BR112022002392A2 (es)
CA (1) CA3150424A1 (es)
CO (1) CO2022002731A2 (es)
IL (1) IL290428A (es)
MX (1) MX2022001743A (es)
PE (1) PE20221252A1 (es)
WO (1) WO2021029854A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230614A1 (es) * 2020-03-13 2023-04-14 Springworks Therapeutics Inc Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas
US11504354B1 (en) * 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
WO2023096954A1 (en) 2021-11-23 2023-06-01 Teva Pharmaceuticals International Gmbh Solid state forms of nirogacestat salts
WO2023174390A1 (zh) * 2022-03-17 2023-09-21 苏州科睿思制药有限公司 尼罗司他二氢溴酸盐的晶型及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084420B (en) * 2004-03-23 2008-07-10 Pfizer Prod Inc Use of imidazole compounds for the treatment of neurodegenerative disorders
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
WO2019053727A1 (en) * 2017-09-18 2019-03-21 Ramot At Tel-Aviv University Ltd. REDIFFERENCING IN VITRO DEVELOPED CELLS FROM HUMAN PANCREATIC ISLAND BEA CELLS ADULPTED BY SMALL MOLECULE INHIBITORS OF THE SIGNALING PATH

Also Published As

Publication number Publication date
JP2022553479A (ja) 2022-12-23
CN114555562A (zh) 2022-05-27
AU2019461090A1 (en) 2022-03-17
PE20221252A1 (es) 2022-08-16
KR20220062510A (ko) 2022-05-17
IL290428A (en) 2022-07-01
WO2021029854A1 (en) 2021-02-18
MX2022001743A (es) 2022-05-10
AR119614A1 (es) 2021-12-29
BR112022002392A2 (pt) 2022-04-26
EP4010322A1 (en) 2022-06-15
CA3150424A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
CO2022002731A2 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
CL2017002022A1 (es) Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
AR112103A1 (es) Compuestos para el tratamiento de tnbc
CL2022000875A1 (es) Inhibidores del factor d del complemento para administración oral
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
PE20211738A1 (es) Formulacion basada en ciclodextrina de un inhibidor de bcl-2
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
SV2011004017A (es) Tratamiento del cancer de pancreas
CO2022015428A2 (es) Compuesto de oxofenilarsina deuterada y uso del mismo
CO2021002980A2 (es) Formulaciones de dendrímeros
AR108792A1 (es) Composiciones que comprenden timolol
AR128051A1 (es) Inhibidores de parp1
AR113817A1 (es) Compuestos útiles para inhibir a cdk7